Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16821065 | 0.94 | EPHX1 (0.50) | RXRARXRBEPHX1FABP7FABP3 | |
| SCHEMBL30833341 | 0.94 | EPHX1 (0.50) | RXRARXRBEPHX1FABP7FABP3 | |
| SCHEMBL2123666 | 0.93 | MAPT (0.47) | RXRARXRBTHRBEPHX1FABP7 | |
| SCHEMBL2124788 | 0.91 | PLG (0.44) | MEN1KMT2ARXRARXRBTHRB | |
| Acetic Acid SCHEMBL6685149 | 0.90 | MAPT (0.48) | RXRARXRBEPHX1FABP7FABP3 | |
| SCHEMBL421454 | 0.90 | KMT2A (0.56) | MEN1KMT2ATHRB | |
| SCHEMBL16436368 | 0.86 | SLC9A1 (0.44) | MEN1KMT2AEPHX1 | |
| SCHEMBL2125460 | 0.85 | LMNA (0.49) | MEN1KMT2ATHRB | |
| SCHEMBL2604627 | 0.84 | CYP1A2 (0.44) | RXRARXRB | |
| SCHEMBL14173221 | 0.84 | KMT2A (0.50) | MEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8313669-B2 | Liquid-crystal display | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-11-20 | — | — | US | disclosed |
| US-8313669-B2 | Liquid-crystal display | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-11-20 | — | — | US | disclosed |
| US-8313669-B2 | Liquid-crystal display | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-11-20 | — | — | US | disclosed |
| EP-2181174-B1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2012-01-25 | — | — | EP | disclosed |
| EP-2181174-B1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-20110101269-A1 | LIQUID-CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110101269-A1 | LIQUID-CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110101269-A1 | LIQUID-CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2181174-A1 | LIQUID CRYSTAL DISPLAY | Merck Patent GmbH (DE) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009030322-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009030322-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110101269-A1 | LIQUID-CRYSTAL DISPLAY | KLK3, LPXN, PSAP | MEN1 1782/4885KMT2A 2905/4885RXRA 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.